Twitter Watch [accessed 10 November 2012 – 01:11]

Twitter Watch  [accessed 10 November 2012 – 01:11]

World Bank @WorldBank
How the economic downturn is affecting #health systems around the world. http://bit.ly/WGgsXt  #longreads
5:20 PM – 9 Nov 12

WHO ‏@WHO
The draft global monitoring framework on noncommunicable diseases is now online – find it here http://goo.gl/jC9Dn  #NCDs
10:35 AM – 9 Nov 12 ·

Doctors w/o Borders ‏@MSF_USA
New research supports the evidence that the two existing rotavirus vaccines may not be best adapted for use in Africa. http://bit.ly/TNInB8 
9:55 AM – 9 Nov 12

PATH @PATHtweets
The director of the PATH Malaria Vaccine Initiative comments on results of recent vaccine trials. See our blog. http://ow.ly/fa747 
9:12 AM – 9 Nov 12

IHME at UW @IHME_UW
Thx 4 sharing! MT@devisridhar Save the Date: Second Global Health Metrics and Evaluation Conference, June 17-19 2013, http://ghme.org 
7:55 AM – 9 Nov 12

The Global Fund @lobalfundnews
Global Fund Appoints Elizabeth O’Donnell as Head of Human Resources http://bitly.com/UzwScV 
7:34 AM – 9 Nov 12

The Global Fund @lobalfundnews
Global Fund Appoints Christopher Game as Chief Procurement Officer http://www.theglobalfund.org/en/mediacenter/newsreleases/2012-11-09_Global_Fund_Appoints_Christopher_Game_as_Chief_Procurement_Officer/ …
5:17 AM – 9 Nov 12

Vaccines:The Week in Review 3 November 2012

Editor’s Notes:

Email Summary: Vaccines: The Week in Review is available as a weekly email summary: please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_3 November 2012

Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.

Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…

WHO: Routine vaccination reaching four in five children but 22 million still miss out

WHO: Routine vaccination reaching four in five children but 22 million still miss out
Note for the media [full text]

1 November 2012 | GENEVA – Four in five children (83%) worldwide received the recommended three doses of diphtheria–tetanus–pertussis (DTP) vaccine during infancy in 2011, according to new data released in the Morbidity and Mortality Weekly Report and in the WHO Weekly Epidemiological Record (WER).

Sustained progress
The new data show sustained progress from the previous two years, and a significant achievement from when WHO’s Expanded Programme on Immunization (EPI) was established nearly 40 years ago. At that time, fewer than 5% of the world’s children were being vaccinated against these three deadly diseases.

Achieving DTP vaccination of infants before they reach 12 months is one of the most important indicators of how effective vaccination programmes are in reaching children with life-saving vaccines.

22 million children still miss out
While substantial progress has been made, the new data show more than 22 million children, mostly living in less-developed countries, missed out on the three basic vaccinations during their first year of life in 2011.

About half of all incompletely vaccinated children live in three countries: India, Indonesia and Nigeria. These countries have large child populations and their immunization programmes are hampered by occasional problems with vaccine supply and inaccessibility of vulnerable populations…

“An accessible and well-functioning immunization programme should be a key component of public health services in every country,” says Dr Jean-Marie Okwo-Bele, Director of WHO’s Department of Immunization, Vaccines and Biologicals. “By supporting countries to strengthen their health systems through the implementation of the new Global Vaccine Action Plan, we can increase global access to vaccines and make an impact on the lives of millions of people.”

Strengthening routine immunization services
An estimated 130 million infants are born each year. Vaccinating these children to protect them from diphtheria, tetanus, whooping cough (pertussis) as well as measles, polio, and other preventable diseases is vital to keeping them alive and healthy. WHO estimates that immunizations save between two and three million lives per year.

Strengthening routine immunization services is crucial to achieve the Millennium Development Goal 4 of reducing deaths among children under-five by two-thirds by 2015 compared to 1990.

http://www.who.int/mediacentre/news/notes/2012/vaccination_20121101/en/index.html

The Weekly Epidemiological Record (WER) for 2 November 2012, vol. 87, 44 (pp. 421–436) includes:
– Outbreak news: Ebola, Democratic Republic of the Congo
– Review of the 2012 winter influenza season, southern hemisphere
– Global routine vaccination coverage, 2011
http://www.who.int/entity/wer/2012/wer8744.pdf

The MMWR Weekly for November 2, 2012 / Vol. 61 / No. 43 includes:
Global Routine Vaccination Coverage, 2011

GAVI Media Release: Malawi to protect thousands of children’s lives with rotavirus vaccines

GAVI Media Release: Malawi to protect thousands of children’s lives with rotavirus vaccines
Malawi becomes the 10th GAVI-supported country to introduce vaccines against most common cause of severe and fatal diarrhoea

Geneva, 29 October 2012 — Malawi has become the latest in a growing number of African countries to introduce rotavirus vaccine into its national immunisation programme, offering its children the best possible protection against the primary cause of severe and fatal diarrhoea.   “This is an important day for all the children of Malawi”, said GAVI Alliance CEO, Dr Seth Berkley. “Rotavirus immunisation is their best hope for protection against rotavirus disease and the deadly dehydrating diarrhoea it can cause.”

http://www.gavialliance.org/library/news/press-releases/2012/malawi-protect-thousands-childrens-lives-rotavirus-vaccines/

IVI appoints Dr. Alejandro Cravioto as Chief Scientific Officer.

IVI – in conjunction with the celebration of the Institute’s 15th Anniversary in October – formally announced the appointment of  Dr. Alejandro Cravioto as Chief Scientific Officer. In this role, Dr. Cravioto will oversee all of the Institute’s scientific affairs and will lend his expertise and advice on matters relevant to vaccine science and technology and potential opportunities. IVI noted that Dr. Cravioto brings a breadth of experience to the Institute. He worked successively as Head of the Research Department and Deputy Director of the National Institute of Health and Technology for Child Health, Director of the Division of Microbiology on the National Institute of Public Health of Cuernavaca, and Professor and Chair of the Department of Public Health of the Faculty of Medicine of the National Autonomous University of Mexico (UNAM) before being appointed as the Dean of the Faculty of Medicine. For the past seven years, he worked as Deputy Director and as Executive Director of the International Centre for Diarrheal Disease Research (icddr,b) in Dhaka, Bangladesh. Most recently in 2011, he was appointed by UN Secretary-General Ban Ki-Moon to head a panel investigating the outbreak of cholera in Haiti.

http://www.ivi.org/web/www/07_03?p_p_id=EXT_BBS&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_EXT_BBS_struts_action=%2Fext%2Fbbs%2Fview_message&_EXT_BBS_messageId=462

GPEI Update: Polio this week – As of 31 Oct 2012

Update: Polio this week – As of 31 Oct 2012
Global Polio Eradication Initiative

[Editor’s Extract]
– The Independent Monitoring Board (IMB) is meeting this week in London, United Kingdom (UK). The IMB is reviewing the latest status of the global polio eradication effort and progress and challenges with implementing national polio emergency action plans in priority countries. The IMB’s meeting report is anticipated to be finalized in November. Reports from partners and presentations by country delegations to the IMB are available here.

– Last week, polio eradication partners from around the world marked World Polio Day. A vast array of awareness- and fund-raising activities took place around the world, including by Rotarians all over the globe – including the maiden voyage of a special Rotary ‘End Polio Now’ express train which will travel Germany’s rail network for the next 12 months. Political and traditional leaders in polio-infected and donor countries publicly offered their support to the global eradication effort, as did development partners and public health leaders. More

– Next week (6-8 November), the Strategic Advisory Group of Experts on immunization (SAGE) is meeting in Geneva, Switzerland, and will devote one meeting session for a detailed review of the current status of the Global Polio Eradication Initiative and plans

Nigeria
– Two new WPV cases were reported in the past week (WPV1s from Kano and Katsina), bringing the total number of WPV cases for 2012 to 99. The most recent WPV case had onset of paralysis on 23 September (WPV1 from Katsina).

Horn of Africa
– Outbreak response is ongoing in Kenya and parts of Somalia, following recent confirmation of a cVDPV2 outbreak in a Somali refugee camp in Dadaab, Kenya, and Kismayo, south-central Somalia.
– Additionally, OPV continues to be added to broader humanitarian response activities. The polio programme is continuing to work closely with other UN agencies, partners and

WHO: World Pneumonia Day – 12 November 2012

WHO: World Pneumonia Day – 12 November 2012

World Pneumonia Day seeks to raise awareness of pneumonia as a public health issue and help prevent the millions of avoidable child deaths from pneumonia that occur each year. It is organized by the Global Coalition against Child Pneumonia (a network of international, government, non-governmental and community-based organizations, research and academic institutions, foundations, and individuals) to bring much-needed attention to pneumonia among donors, policy makers, health care professionals, and the general public. http://www.who.int/mediacentre/events/annual/world_pneumonia_day/en/index.html

13th Annual General Meeting- DCVMN (Developing Country Vaccine Manufacturers Network) 31 October – 3 November 2012

13th Annual General Meeting- DCVMN (Developing Country Vaccine Manufacturers Network)
31 October – 3 November 2012
Bali – Indonesia

DCVMN has the following objectives within developing countries:

– To promote consistent and sustainable supply of quality vaccines at an affordable price.

– To combat infectious diseases especially those from the developing world, by strengthening the capacity of vaccine, vaccine related product manufactures, and potentially other health technology producers.

– To encourage Research and Development efforts meeting emerging vaccine needs.

– To foster production and delivery of high quality vaccines and other health technologies effectively on a long term basis for national immunization programmes.

Meeting Agenda: http://www.13thdcvmn.com/index.php?option=com_content&view=article&id=50&Itemid=63

IOM Report: An Integrated Framework for Assessing the Value of Community-Based Prevention

IOM Report: An Integrated Framework for Assessing the Value of Community-Based Prevention
November 2, 2012
Type: Consensus Report
Board: Board on Population Health and Public Health Practice

Over the last century, the major causes of disease and death among Americans have changed, shifting from predominantly communicable diseases spread by germs to chronic ailments. This shift has been accompanied by a deeper understanding about what keeps people healthy or leaves them vulnerable to becoming ill. To get at the heart of the challenges to living a healthy life, we must increasingly emphasize factors that affect today’s causes of morbidity and mortality.

Despite their importance to preventing illness, determining the value of community-based interventions has proven difficult. Preventing illness requires immediate investments with benefits that might not be realized for many years.

This report proposes a framework to assess the value of community-based, non-clinical prevention policies and wellness strategies. The framework represents a valuable step toward realizing the elusive goal of appropriately and comprehensively valuing community-based prevention.

http://www.iom.edu/Reports/2012/An-Integrated-Framework-for-Assessing-the-Value-of-Community-Based-Prevention.aspx

WHO/WMO: Atlas of Health and Climate

WHO/WMO: Atlas of Health and Climate
October 2012
WHO and the World Meteorological Organization (WMO) jointly published a new atlas that represents “a unique collaboration between the meteorological and public health communities. It provides sound scientific information on the connections between weather and climate and major health challenges. These range from diseases of poverty to emergencies arising from extreme weather events and disease outbreaks. They also include environmental degradation, the increasing prevalence of noncommunicable diseases and the universal trend of demographic ageing.”

http://www.who.int/globalchange/publications/atlas/report/en/index.html

Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010–2011

BMC Public Health
(Accessed 3 November 2012)
http://www.biomedcentral.com/bmcpublichealth/content

Research article  
Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010–2011
Dominique Baratin, Corinne Signore, Jacques Thierry, Evelyne Caulin, Philippe Vanhems BMC Public Health 2012, 12:940 (1 November 2012)
Open Access

Abstract (provisional)
Background
Compliance with official recommendations can be assessed by evaluating vaccination coverage (VC) in populations. The main objective of our study was to assess VC of adults against diphtheria, tetanus, poliomyelitis and pertussis (dTPaP) according to age. The second objective was to explore if vaccination status could be confirmed by documentation.

Methods
A cross-sectional study was conducted in 680 adults consulting for biological examination in private laboratories in Lyon (France) to evaluate VC for diphtheria, tetanus, poliomyelitis and pertussis (dTPaP) and enabled reported vaccinations to be compared with documented, confirmed vaccinations.

Results
Verification of documented, confirmed vaccinations disclosed VC of 78.7% for tetanus, 63.6% for poliomyelitis, 57.8% for diphtheria and 10.7% for pertussis. Comparison of confirmed and self-reported vaccinations revealed that a large percentage of people who thought that they were vaccinated were not. VC significantly decreased with age for diphtheria and poliomyelitis and did not vary by gender. The VC rate for pertussis has increased since the 2008 recommendations were made.

Conclusions
The main thrust of this study was to compare reported and confirmed data. A significant percentage of people wrongly believed that they were up to date with their vaccination.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany

BMC Public Health
(Accessed 3 November 2012)
http://www.biomedcentral.com/bmcpublichealth/content

Research article  
Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany
Merle M Böhmer, Dietmar Walter, Gerhard Falkenhorst, Stephan Müters, Gérard Krause, Ole Wichmann
BMC Public Health 2012, 12:938 (31 October 2012)
Open Access

Abstract (provisional)
Background
In Germany, annual vaccination against seasonal influenza is recommended for certain target groups (e.g. persons aged [greater than or equal to] 60 years, chronically ill persons, healthcare workers (HCW)). In season 2009/10, vaccination against pandemic influenza A(H1N1)pdm09, which was controversially discussed in the public, was recommended for the whole population. The objectives of this study were to assess vaccination coverage for seasonal (seasons 2008/09-2010/11) and pandemic influenza (season 2009/10), to identify predictors of and barriers to pandemic vaccine uptake and whether the controversial discussions on pandemic vaccination has had a negative impact on seasonal influenza vaccine uptake in Germany.

Methods
We analysed data from the ‘German Health Update’ (GEDA10) telephone survey (n=22,050) and a smaller GEDA10-follow-up survey (n=2,493), which were both representative of the general population aged [greater than or equal to]18 years living in Germany.

Results
Overall only 8.8% of the adult population in Germany received a vaccination against pandemic influenza. High socioeconomic status, having received a seasonal influenza shot in the previous season, and belonging to a target group for seasonal influenza vaccination were independently associated with the uptake of pandemic vaccines. The main reasons for not receiving a pandemic vaccination were ‘fear of side effects’ and the opinion that ‘vaccination was not necessary’. Seasonal influenza vaccine uptake in the pre-pandemic season 2008/09 was 52.8% among persons aged [greater than or equal to]60 years; 30.5% among HCW, and 43.3% among chronically ill persons. A decrease in vaccination coverage was observed across all target groups in the first post-pandemic season 2010/11 (50.6%, 25.8%, and 41.0% vaccination coverage, respectively).

Conclusions
Seasonal influenza vaccination coverage in Germany remains in all target groups below 75%, which is a declared goal of the European Union. Our results suggest that controversial public discussions about safety and the benefits of pandemic influenza vaccination may have contributed to both a very low uptake of pandemic vaccines and a decreased uptake of seasonal influenza vaccines in the first post-pandemic season. In the upcoming years, the uptake of seasonal influenza vaccines should be carefully monitored in all target groups to identify if this trend continues and to guide public health authorities in developing more effective vaccination and communication strategies for seasonal influenza vaccination.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Human papilloma virus vaccination programs reduce health inequity in most scenarios: a Simulation Study

BMC Public Health
(Accessed 3 November 2012)
http://www.biomedcentral.com/bmcpublichealth/content

Research article  
Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation Study
Natasha S Crowcroft, Jemila S Hamid, Shelley L Deeks, John Frank BMC Public Health 2012, 12:935 (31 October 2012)
Open Access

Abstract (provisional)
Background
The global and within-country epidemiology of cervical cancer exemplifies health inequity. Public health programs may reduce absolute risk but increase inequity; inequity may be further compounded by screening programs. In this context, we aimed to explore what the impact of human papillomavirus (HPV) vaccine might have on health equity allowing for uncertainty surrounding the long-term effect of HPV vaccination programs.

Methods
A simple static multi-way sensitivity analysis was carried out to compare the relative risk, comparing after to before implementation of a vaccination program, of infections which would cause invasive cervical cancer if neither prevented nor detected, using plausible ranges of vaccine effectiveness, vaccination coverage, screening sensitivity, screening uptake and changes in uptake.

Results
We considered a total number of 3,793,902 scenarios. In 63.9% of scenarios considered, vaccination would lead to a better outcome for a population or subgroup with that combination of parameters. Regardless of vaccine effectiveness and coverage, most simulations led to lower rates of disease.

Conclusions
If vaccination coverage and screening uptake are high, then communities are always better off with a vaccination program. The findings highlight the importance of achieving and maintaining high immunization coverage and screening uptake in high risk groups in the interest of health equity.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

BMC Public Health
(Accessed 3 November 2012)
http://www.biomedcentral.com/bmcpublichealth/content

Research article  
Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
Zoltán Vokó, László Nagyjánosi, Zoltán Kaló BMC Public Health 2012, 12:924 (30 October 2012)

Open Access
Abstract (provisional)
Background
The cervical cancer screening program implemented in Hungary to date has not been successful. Along with screening, vaccination is an effective intervention to prevent cervical cancer. The aim of this study was to assess the cost-effectiveness of adding vaccination with the human papillomavirus 16/18 vaccine to the current cervical cancer screening program in Hungary.

Methods
We developed a cohort simulation state-transition Markov model to model the life course of 12-year-old girls. Eighty percent participation in the HPV vaccination program at 12 years of age was assumed. Transitional probabilities were estimated using data from the literature. Local data were used regarding screening participation rates, and the costs were estimated in US $. We applied the purchasing power parity exchange rate of 129 HUF/$ to the cost data. Only direct health care costs were considered. We used a 3.7% discount rate for both the cost and quality-adjusted life years (QALYs). The time horizon was 88 years.

Results
Inclusion of HPV vaccination at age 12 in the cervical cancer prevention program was predicted to be cost-effective. The incremental cost-effectiveness ratio (ICER) of adding HPV vaccination to the current national cancer screening program was estimated to be 27 588 $/QALY. The results were sensitive to the price of the vaccine, the discount rate, the screening participation rate and whether herd immunity was taken into account.

Conclusions
Our modeling analysis showed that the vaccination of 12-year-old adolescent girls against cervical cancer with the AS04-adjuvanted human papillomavirus 16/18 vaccine would be a cost-effective strategy to prevent cervical cancer in Hungary.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Analysis: Future of WHO hangs in the balance

British Medical Journal
03 November 2012 (Vol 345, Issue 7881)
http://www.bmj.com/content/345/7881

Analysis
Future of WHO hangs in the balance
BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6877 (Published 25 October 2012)
Cite this as: BMJ 2012;345:e6877
http://www.bmj.com/content/345/bmj.e6877

BMJ Excerpt
   WHO is in crisis. Unless member states can be persuaded to “untie” their donations and give the organisation leeway to control its budget and set priorities WHO will slide further into irrelevance with disastrous consequences for global health, warns David Legge

A substantial shortfall in the funds available for basic administrative functions led WHO’s director general, Margaret Chan, to initiate another reform of the WHO in 2010. Although the reform programme has expanded to include priority setting, governance, and management,1 financing is the fundamental problem. The process of reform is also bedevilled by the same problem that led to the funding crisis in the first place—a switch in power from the assembly of member states to donors (including some member states as well as other donors) with specific interests. This article outlines the problems and what the reforms are trying to achieve.

When WHO was formed in 1948 its main funding came from its member states, who paid according to the size of their population and economy (their “assessed contributions”),2 but since its founding the large rich countries (the United States in particular) have sought to control WHO’s agenda by restricting its funding.3 Since the 1980s assessed contributions have been frozen, and the WHO has become increasingly reliant on voluntary contributions from member states, intergovernmental bodies, and various philanthropists. Assessed contributions as a proportion of total revenues have declined from 80% in 1978-79 to 25% in 2010-11. The budgetary gap has been met through the growth in voluntary contributions, 91% of which are earmarked for particular projects and programmes. As a consequence, WHO’s work is controlled by the donors rather than by its assembly of member states, distorting priorities and the coherence of its programmes.

Success of the current reform programme depends on resolving the contradiction between…

Parental perceptions surrounding polio and self-reported non-participation in polio supplementary immunization activities in Karachi, Pakistan: a mixed methods study

Bulletin of the World Health Organization
Volume 90, Number 11, November 2012, 793-868
http://www.who.int/bulletin/volumes/90/11/en/index.html

Parental perceptions surrounding polio and self-reported non-participation in polio supplementary immunization activities in Karachi, Pakistan: a mixed methods study
Asif Raza Khowaja, Sher Ali Khan, Naveeda Nizam, Saad Bin Omer & Anita Zaidi

Objective
To assess parent’s knowledge and perceptions surrounding polio and polio vaccination, self-reported participation in polio supplementary immunization activities (SIAs) targeting children aged < 5 years, and reasons for non-participation.

Methods
The mixed methods study began with a cross-sectional survey in Karachi, Pakistan. A structured questionnaire was administered to assess parental knowledge of polio and participation in polio SIAs conducted in September and October 2011. Additionally, 30 parents of Pashtun ethnicity (a high-risk group) who refused to vaccinate their children were interviewed in depth to determine why. Descriptive and bivariate analyses by ethnic and socioeconomic group were performed for quantitative data; thematic analysis was conducted for qualitative interviews with Pashtun parents.

Findings
Of 1017 parents surveyed, 412 (41%) had never heard of polio; 132 (13%) did not participate in one SIA and 157 (15.4%) did not participate in either SIA. Among non-participants, 34 (21.6%) reported not having been contacted by a vaccinator; 116 (73.9%) reported having refused to participate, and 7 (4.5%) reported that the child was absent from home when the vaccinator visited. Refusals clustered in low-income Pashtun (43/441; 9.8%) and high-income families of any ethnic background (71/153; 46.4%). Low-income Pashtuns were more likely to not have participated in polio SIAs than low-income non-Pashtuns (odds ratio, OR: 7.1; 95% confidence interval, CI: 3.47–14.5). Reasons commonly cited among Pashtuns for refusing vaccination included fear of sterility; lack of faith in the polio vaccine; scepticism about the vaccination programme, and fear that the vaccine might contain religiously forbidden ingredients.

Conclusion
In Karachi, interruption of polio transmission requires integrated and participatory community interventions targeting high-risk populations.

Use of evidence to support healthy public policy: a policy effectiveness–feasibility loop

Bulletin of the World Health Organization
Volume 90, Number 11, November 2012, 793-868
http://www.who.int/bulletin/volumes/90/11/en/index.html

Use of evidence to support healthy public policy: a policy effectiveness–feasibility loop
Sarah Bowman, Nigel Unwin, Julia Critchley, Simon Capewell, Abdullatif Husseini, Wasim Maziak, Shahaduz Zaman, Habiba Ben Romdhane, Fouad Fouad, Peter Phillimore, Belgin Unal, Rana Khatib, Azza Shoaibi & Balsam Ahmad

Public policy plays a key role in improving population health and in the control of diseases, including non-communicable diseases. However, an evidence-based approach to formulating healthy public policy has been difficult to implement, partly on account of barriers that hinder integrated work between researchers and policy-makers. This paper describes a “policy effectiveness–feasibility loop” (PEFL) that brings together epidemiological modelling, local situation analysis and option appraisal to foster collaboration between researchers and policy-makers. Epidemiological modelling explores the determinants of trends in disease and the potential health benefits of modifying them. Situation analysis investigates the current conceptualization of policy, the level of policy awareness and commitment among key stakeholders, and what actually happens in practice, thereby helping to identify policy gaps.   Option appraisal integrates epidemiological modelling and situation analysis to investigate the feasibility, costs and likely health benefits of various policy options. The authors illustrate how PEFL was used in a project to inform public policy for the prevention of cardiovascular diseases and diabetes in four parts of the eastern Mediterranean. They conclude that PEFL may offer a useful framework for researchers and policy-makers to successfully work together to generate evidence-based policy, and they encourage further evaluation of this approach.

Decision-making on malaria vaccine introduction: the role of cost–effectiveness analyses

Bulletin of the World Health Organization
Volume 90, Number 11, November 2012, 793-868
http://www.who.int/bulletin/volumes/90/11/en/index.html

Decision-making on malaria vaccine introduction: the role of cost–effectiveness analyses
Vasee S Moorthy, Raymond Hutubessy, Robert D Newman & Joachim Hombach
Bulletin of the World Hhttp://www.who.int/bulletin/volumes/90/11/12-107482/en/index.htmlealth Organization 2012;90:864-866. doi: 10.2471/BLT.12.107482
Status of malaria vaccine development
Policy-makers in countries where malaria is endemic are facing increasingly complex decisions about which vaccines and malaria prevention measures to include in national immunization and malaria control programmes. Several new vaccines and malaria preventive measures are already competing for limited financing in developing countries. African countries with endemic malaria should be ready to make a national policy decision on the introduction of RTS,S/AS01, a first-generation malaria vaccine, by 2015.1 If clinical trials progress according to schedule, that same year the World Health Organization (WHO) will issue a policy recommendation on the public health use of this vaccine based on the findings of the full Phase III efficacy trial in progress, which will be available in late 2014.2 The vaccine’s manufacturers are targeting infants in malaria-endemic African countries who undergo routine vaccination through the Expanded Programme on Immunization (EPI) at 6, 10 and 14 weeks of age, with the possibility of a booster dose being needed at 9–18 months. At present WHO is assessing the evidence base for a policy position on this vaccine. The type of critical data that it will take into account during this process is shown in Box 1.

Box 1. Critical questions for formulation of policy on a new malaria vaccine

– What is the evidence that RTS,S/AS01 vaccination is not associated with serious adverse reactions in children aged less than 17 months?

– What level of protection against clinical malaria does RTS,S/AS01 confer on infants 6 to 14 weeks of age, over 30 months of follow-up, when co-administered with routine infant vaccines in sub-Saharan African settings?

– What is the evidence that a booster dose of RTS,S/AS01 at 18 months is needed to maintain benefit following a 3-dose primary immunization series?

– Is there evidence that the efficacy of RTS,S/AS01 varies in different transmission settings?

– Do available data support a WHO policy recommendation to introduce RTS,S/AS01 into routine immunization programmes in malaria-endemic countries? What is the optimal schedule? What flexibility is there for interrupted and delayed schedules?

– What is the evidence that co-administration leads to non-inferior responses for both RTS,S/AS01 and existing EPI vaccines?

– What is the evidence that RTS,S/AS01, when administered at 6,10 and14 weeks of age, provides at least as much protection against hepatitis B as the available hepatitis B vaccines?

– How cost–effective is RTS,S/AS01 as a preventive measure in addition to LLINs?

Cost–effectiveness is an important consideration in public health decision-making. This article summarizes critical parameters driving malaria vaccine cost–effectiveness predictions and discusses major uncertainties that remain in the cost–effectiveness modelling arena. It also highlights the need for ongoing work by modelling groups to further refine cost–effectiveness predictions….

Opinion: Health Systems Perspectives – Infectious Diseases of Poverty

Infectious Diseases of Poverty
2012, 1
http://www.idpjournal.com/content
[Accessed 3 November 2012]

Opinion  
Health Systems Perspectives – Infectious Diseases of Poverty
Dale Huntington Infectious Diseases of Poverty 2012, 1:12 (1 November 2012)
Open Access

Abstract (provisional)
The right to health as a fundamental human right is enshrined in the World Health Organization’s charter and has been reaffirmed in international agreements spanning decades. This new journal reminds us of the essential characteristic of poverty as a violent abuse of human rights. The context of poverty – its social, political and economic dimensions – remain in the reader’s mind as evidence is provided on technical solutions to managing the infectious diseases that afflict poor populations world-wide. Applying a health systems framework to a discussion on infectious diseases of poverty emerges from the papers in this journal’s first edition. Many of the articles discuss treatments, indicating the importance of pharmaceuticals for neglected diseases. Delivery strategies to reach impoverished populations also figure within this first round of papers. Innovative programs that provide diagnostics and treatment for infectious diseases to hard-to-reach rural and urban communities are needed clearly needed, and some good examples are discussed here. Future editions will explore other health system components, broadening the evidence base to increase understanding of effective and sustainable interventions to reduce the burden of infectious disease among the poor. The editors are to be congratulated on the release of this inaugural issue of the journal Infectious Diseases of Poverty. We look forward to reading subsequent editions.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Editorial & Article: Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

Journal of Infectious Diseases
Volume 206 Issue 11 December 1, 2012
http://www.journals.uchicago.edu/toc/jid/current

EDITORIAL COMMENTARIES
Editor’s choice: Monitoring HPV Vaccine Impact: Early Results and Ongoing Challenges
Susan Hariri and Lauri Markowitz
J Infect Dis. (2012) 206(11): 1633-1635 doi:10.1093/infdis/jis593

(See the Major Article by Tabrizi et al, on pages 1645–51.)

Extract
In this issue of the Journal of Infectious Diseases, Tabrizi and colleagues present new data from Australia on genital human papillomavirus (HPV) infection prevalence in the periods immediately before and after HPV vaccine introduction [1]. Based on cross-sectional studies of women aged 18–24 years who received Papanicolaou screening in selected family planning clinics throughout the country, the authors report a 20% decrease in overall genital HPV prevalence and a more dramatic decrease of 77% in HPV types targeted by the quadrivalent vaccine (HPV types 6, 11, 16, and 18) from the 2 years before (2005–2007) to the 2 years after (2009–2010) the vaccine was widely implemented through a government-funded program. In addition to comparing HPV prevalence trends across periods, Tabrizi et al obtained HPV vaccination history from participants to more directly evaluate the effect of vaccination on HPV prevalence. Their results indicate significantly lower vaccine-type HPV prevalence among vaccinated women in the postvaccine sample (5.0%) compared with both unvaccinated women from the same period (15.8%) and women from the prevaccine period (28.7%). Using the age-adjusted HPV prevalence ratio of vaccinated to unvaccinated women, the authors calculate a vaccine effectiveness of 73% against infection with any of the 4 vaccine types.

Because the major benefit of HPV vaccination—prevention of cervical and other less common HPV-associated cancers—will not be evident for decades, a spectrum of intermediate outcomes are being monitored to assess the early impact of HPV vaccines. Although considered to be the simplest and earliest indicator of vaccine impact, a reduction in HPV vaccine type prevalence may not be sufficient to guide vaccine policy and practices. Therefore, in addition to ongoing HPV type prevalence monitoring, cancer and precancer outcomes as well as HPV-associated genital warts are …

MAJOR ARTICLES AND BRIEF REPORTS
VIRUSES
Editor’s choice: Fall in Human Papillomavirus Prevalence Following a National Vaccination Program
Sepehr N. Tabrizi, Julia M. L. Brotherton, John M. Kaldor, S. Rachel Skinner, Eleanor Cummins, Bette Liu, Deborah Bateson, Kathleen McNamee, Maria Garefalakis, and Suzanne M. Garland
J Infect Dis. (2012) 206(11): 1645-1651 doi:10.1093/infdis/jis590

Abstract
Background. In April 2007, Australia became the first country to introduce a national government-funded human papillomavirus (HPV) vaccination program. We evaluated the program’s impact on genotype-specific HPV infection prevalence through a repeat survey of women attending clinical services.

Methods. HPV genoprevalence in women aged 18–24 years attending family planning clinics in the prevaccine period (2005–2007) was compared with prevalence among women of the same age group in the postvaccine period (2010–2011). The same recruitment and testing strategies were utilized for both sets of samples, and comparisons were adjusted for potentially confounding variables.

Results. The prevalence of vaccine HPV genotypes (6, 11, 16, and 18) was significantly lower in the postvaccine sample than in the  prevaccine sample (6.7% vs 28.7%; P < .001), with lower prevalence observed in both vaccinated and unvaccinated women compared with the prevaccine population (5.0% [adjusted odds ratio, 0.11; 95% confidence interval, 0.06–0.21] and 15.8% [adjusted odds ratio, 0.42; 95% confidence interval, 0.19–0.93], respectively). A slightly lower prevalence of nonvaccine oncogenic HPV genotypes was also found in vaccinated women (30.8% vs 37.6%; adjusted odds ratio, 0.68; 95% confidence interval, 0.46–0.99).

Conclusions. Four years after the commencement of the Australian HPV vaccination program, a substantial decrease in vaccine-targeted genotypes is evident and should, in time, translate into reductions in HPV-related lesions.

Comment: Dengue vaccine development. Thai schoolchildren randomised, controlled phase 2b trial

The Lancet  
Nov 03, 2012  Volume 380  Number 9853  p1531 – 1620  e8 – 9
http://www.thelancet.com/journals/lancet/issue/current

Comment
Dengue vaccine development: a 75% solution?
Scott B Halstead

Preview
A completed clinical trial of vaccine efficacy should be cause for celebration for the billions of people who live in the 128 countries where dengue viruses (DENV) are transmitted.1,2 However, the celebration will be muted this time, as was the case after announcement of results of early clinical trials of vaccines for malaria and HIV.3,4 The low efficacies reported from trials of malaria and HIV vaccines were not entirely unexpected, since these pathogens are known for antigenic complexity and for their ability to successfully evade immune elimination.

Articles
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, Kriengsak Limkittikul, Pornthep Chanthavanich, Saravudh Suvannadabba, Vithaya Jiwariyavej, Wut Dulyachai, Krisana Pengsaa, T Anh Wartel, Annick Moureau, Melanie Saville, Alain Bouckenooghe, Simonetta Viviani, Nadia G Tornieporth, Jean Lang

Summary
Background
Roughly half the world’s population live in dengue-endemic countries, but no vaccine is licensed. We investigated the efficacy of a recombinant, live, attenuated tetravalent dengue vaccine.

Methods
In this observer-masked, randomised, controlled, monocentre, phase 2b, proof-of-concept trial, healthy Thai schoolchildren aged 4—11 years were randomly assigned (2:1) to receive three injections of dengue vaccine or control (rabies vaccine or placebo) at months 0, 6, and 12. Randomisation was by computer-generated permuted blocks of six and participants were assigned with an interactive response system. Participants were actively followed up until month 25. All acute febrile illnesses were investigated. Dengue viraemia was confirmed by serotype-specific RT-PCR and non-structural protein 1 ELISA. The primary objective was to assess protective efficacy against virologically confirmed, symptomatic dengue, irrespective of severity or serotype, occurring 1 month or longer after the third injection (per-protocol analysis). This trial is registered at ClinicalTrials.gov, NCT00842530.

Findings
4002 participants were assigned to vaccine (n=2669) or control (n=1333). 3673 were included in the primary analysis (2452 vaccine, 1221 control). 134 cases of virologically confirmed dengue occurred during the study. Efficacy was 30·2% (95% CI −13·4 to 56·6), and differed by serotype. Dengue vaccine was well tolerated, with no safety signals after 2 years of follow-up after the first dose.

Interpretation
These data show for the first time that a safe vaccine against dengue is possible. Ongoing large-scale phase 3 studies in various epidemiological settings will provide pivotal data for the CYD dengue vaccine candidate.

Funding
Sanofi Pasteur.

Hepatitis E vaccine debuts

Nature  
Volume 491 Number 7422 pp7-154  1 November 2012
http://www.nature.com/nature/current_issue.html

News in Focus
Hepatitis E vaccine debuts
Success of Chinese biotech partnership raises hopes for prevention of overlooked diseases.
Soo Bin Park

Batches of the world’s first vaccine against the hepatitis E virus began rolling out of a Chinese factory last week, promising to stem a disease that every year infects about 20 million people and claims 70,000 lives. The vaccine is being hailed as a victory for an unusual public–private partnership that could set a precedent in China’s burgeoning biotechnology sector, and help to deliver other vaccines for diseases overlooked in the West…

http://www.nature.com/news/hepatitis-e-vaccine-debuts-1.11687

Mumps Outbreak in Orthodox Jewish Communities in the United States

New England Journal of Medicine
November 1, 2012  Vol. 367 No. 18
http://content.nejm.org/current.shtml

Original Aticles
Mumps Outbreak in Orthodox Jewish Communities in the United States
A.E. Barskey and Others

Background
By 2005, vaccination had reduced the annual incidence of mumps in the United States by more than 99%, with few outbreaks reported. However, in 2006, a large outbreak occurred among highly vaccinated populations in the United States, and similar outbreaks have been reported worldwide. The outbreak described in this report occurred among U.S. Orthodox Jewish communities during 2009 and 2010.

Methods
Cases of salivary-gland swelling and other symptoms clinically compatible with mumps were investigated, and demographic, clinical, laboratory, and vaccination data were evaluated.

Results
From June 28, 2009, through June 27, 2010, a total of 3502 outbreak-related cases of mumps were reported in New York City, two upstate New York counties, and one New Jersey county. Of the 1648 cases for which clinical specimens were available, 50% were laboratory-confirmed. Orthodox Jewish persons accounted for 97% of case patients. Adolescents 13 to 17 years of age (27% of all patients) and males (78% of patients in that age group) were disproportionately affected. Among case patients 13 to 17 years of age with documented vaccination status, 89% had previously received two doses of a mumps-containing vaccine, and 8% had received one dose. Transmission was focused within Jewish schools for boys, where students spend many hours daily in intense, face-to-face interaction. Orchitis was the most common complication (120 cases, 7% of male patients ≥12 years of age), with rates significantly higher among unvaccinated persons than among persons who had received two doses of vaccine.

Conclusions
The epidemiologic features of this outbreak suggest that intense exposures, particularly among boys in schools, facilitated transmission and overcame vaccine-induced protection in these patients. High rates of two-dose coverage reduced the severity of the disease and the transmission to persons in settings of less intense exposure.

Sexual Activity–Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds

Pediatrics
November 2012, VOLUME 130 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml

Sexual Activity–Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds
Robert A. Bednarczyk, Robert Davis, Kevin Ault, Walter Orenstein, and Saad B. Omer
Pediatrics 2012; 130:798-805

Abstract
OBJECTIVE: Previous surveys on hypothesized sexual activity changes after human papillomavirus (HPV) vaccination may be subject to self-response biases. To date, no studies measured clinical markers of sexual activity after HPV vaccination. This study evaluated sexual activity–related clinical outcomes after adolescent vaccination.

METHODS: We conducted a retrospective cohort study utilizing longitudinal electronic data from a large managed care organization. Girls enrolled in the managed care organization, aged 11 through 12 years between July 2006 and December 2007, were classified by adolescent vaccine (HPV; tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed; quadrivalent meningococcal conjugate) receipt. Outcomes (pregnancy/sexually transmitted infection testing or diagnosis; contraceptive counseling) were assessed through December 31, 2010, providing up to 3 years of follow-up. Incidence rate ratios comparing vaccination categories were estimated with multivariate Poisson regression, adjusting for health care–seeking behavior and demographic characteristics.

RESULTS: The cohort included 1398 girls (493 HPV vaccine–exposed; 905 HPV vaccine–unexposed). Risk of the composite outcome (any pregnancy/sexually transmitted infection testing or diagnosis or contraceptive counseling) was not significantly elevated in HPV vaccine–exposed girls relative to HPV vaccine–unexposed girls (adjusted incidence rate ratio: 1.29, 95% confidence interval [CI]: 0.92 to1.80; incidence rate difference: 1.6/100 person-years; 95% CI: −0.03 to 3.24). Incidence rate difference for Chlamydia infection (0.06/100 person-years [95% CI: −0.30 to 0.18]) and pregnancy diagnoses (0.07/100 person-years [95% CI: −0.20 to 0.35]), indicating little clinically meaningful absolute risk differences.

CONCLUSIONS: HPV vaccination in the recommended ages was not associated with increased sexual activity–related outcome rates.

Physician Attitudes Regarding School-Located Vaccinations

Pediatrics
November 2012, VOLUME 130 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml

Physician Attitudes Regarding School-Located Vaccinations
Emily V. McCormick, Josh Durfee, Tara M. Vogt, Matthew F. Daley, Simon J. Hambidge, and Judith Shlay
Pediatrics 2012; 130:887-896

Abstract
OBJECTIVE: To assess physician attitudes regarding school-located adolescent vaccination and influenza vaccination.

METHODS: From July through September 2010, a 20-item survey was mailed to 1337 practicing Colorado family physicians and pediatricians. Standard statistical methods were used to examine unadjusted and adjusted odds ratios of factors associated with physician support for school-located vaccination programs.

RESULTS: Overall, 943 physicians were survey-eligible, and 584 (62%) responded. More than half of physicians supported both school-located influenza and adolescent vaccination. However, fewer physicians supported school-located adolescent vaccination compared with influenza vaccination. More physicians supported school-located vaccination for their publicly insured patients compared with their privately insured patients. Some family physicians (32%) and pediatricians (39%) believed that school-located vaccination would make their patients less likely to attend well-child visits, and half of respondents believed that school-located vaccination would have a negative financial impact on their practice. In multivariate analyses, physicians concerned about the financial impact of school-located vaccination were less likely to support such programs.

CONCLUSIONS: Although a majority of Colorado physicians supported influenza and adolescent vaccination at school, they expressed concerns regarding the implications on their practice. Lesser support for vaccination of their privately insured patients and concerns regarding attendance at well-child visits suggests the perceived financial impact from school-located vaccination is a barrier and merits additional examination.

A Quantitative and Novel Approach to the Prioritization of Zoonotic Diseases in North America: A Public Perspective

PLoS One
[Accessed 3 November 2012]
http://www.plosone.org/article/browse.action;jsessionid=577FD8B9E1F322DAA533C413369CD6F3.ambra01?field=date

A Quantitative and Novel Approach to the Prioritization of Zoonotic Diseases in North America: A Public Perspective
Victoria Ng, Jan M.
PLoS ONE: Research Article, published 01 Nov 2012 10.1371/journal.pone.0048519

Abstract
Background
Zoonoses account for over half of all communicable diseases causing illness in humans. As there are limited resources available for the control and prevention of zoonotic diseases, a framework for their prioritization is necessary to ensure resources are directed into those of highest importance. Although zoonotic outbreaks are a significant burden of disease in North America, the systematic prioritization of zoonoses in this region has not been previously evaluated.

Methodology/Principal Findings
This study describes the novel use of a well-established quantitative method, conjoint analysis (CA), to identify the relative importance of 21 key characteristics of zoonotic diseases that can be used for their prioritization in Canada and the US. Relative importance weights from the CA were used to develop a point-scoring system to derive a recommended list of zoonoses for prioritization in Canada and the US. Over 1,500 participants from the general public were recruited to complete the online survey (761 from Canada and 778 from the US). Hierarchical Bayes models were fitted to the survey data to derive CA-weighted scores. Scores were applied to 62 zoonotic diseases of public health importance in Canada and the US to rank diseases in order of priority.

Conclusions/Significance
This was the first study to describe a systematic and quantitative approach to the prioritization of zoonoses in North America involving public participants. We found individuals with no prior knowledge or experience in prioritizing zoonoses were capable of producing meaningful results using CA as a novel quantitative approach to prioritization. More similarities than differences were observed between countries suggesting general agreement in disease prioritization between Canadians and Americans. We demonstrate CA as a potential tool for the prioritization of zoonoses; other prioritization exercises may also consider this approach.

Parental Acceptance of HPV Vaccine in Peru: A Decision Framework

PLoS One
[Accessed 3 November 2012]
http://www.plosone.org/article/browse.action;jsessionid=577FD8B9E1F322DAA533C413369CD6F3.ambra01?field=date

Parental Acceptance of HPV Vaccine in Peru: A Decision Framework
Rosario M. Bartolini, Jennifer L. Winkler, Mary E. Penny, D. Scott LaMontagne
PLoS ONE: Research Article, published 29 Oct 2012 10.1371/journal.pone.0048017

Abstract 
Objective and Method
Cervical cancer is the third most common cancer affecting women worldwide and it is an important cause of death, especially in developing countries. Cervical cancer is caused by human papillomavirus (HPV) and can be prevented by HPV vaccine. The challenge is to expand vaccine availability to countries where it is most needed. In 2008 Peru’s Ministry of Health implemented a demonstration project involving 5th grade girls in primary schools in the Piura region. We designed and conducted a qualitative study of the decision-making process among parents of girls, and developed a conceptual model describing the process of HPV vaccine acceptance.

Results
We found a nonlinear HPV decision-making process that evolved over time. Initially, the vaccine’s newness, the requirement of written consent, and provision of information were important. If information was sufficient and provided by credible sources, many parents accepted the vaccine. Later, after obtaining additional information from teachers, health personnel, and other trusted sources, more parents accepted vaccination. An understanding of the issues surrounding the vaccine developed, parents overcome fears and rumors, and engaged in family negotiations–including hearing the girl’s voice in the decision-making process. The concept of prevention (cancer as danger, future health, and trust in vaccines) combined with pragmatic factors (no cost, available at school) and the credibility of the offer (information in the media, recommendation of respected authority figure) were central to motivations that led parents to decide to vaccinate their daughters. A lack of confidence in the health system was the primary inhibitor of vaccine acceptance.

Conclusions
Health personnel and teachers are credible sources of information and can provide important support to HPV vaccination campaigns.

Editorial: Bringing Clarity to the Reporting of Health Equity

PLoS Medicine
(Accessed 3 November 2012)
http://www.plosmedicine.org/article/browse.action?field=date

Bringing Clarity to the Reporting of Health Equity
The PLOS Medicine Editors Editorial, published 30 Oct 2012
doi:10.1371/journal.pmed.1001334

Health equity—the absence of avoidable and unfair differences in health, including access to health care—is relevant to virtually the whole of medicine and public health and encompasses much more than inequality alone. WHO [1] notes specifically that “health inequities involve more than inequality—whether in health determinants or outcomes, or in access to the resources needed to improve and maintain health—but [is also] also a failure to avoid or overcome such inequality that infringes human rights norms or is otherwise unfair.”

Inequity in health is widespread, is itself unevenly distributed globally within and between countries, and contributes to inequity in other areas of society more generally; two recent examples show that health inequity leads to disabled individuals in the UK having less access to cancer screening [2] and older people in Latin America, China, India, and Nigeria being excluded from access to health care because of health systems that finance medical services through out-of-pocket payments [3].

The WHO Commission on Social Determinants of Health (CSDH), which defined health equity as the absence of systematic differences in health, between and within countries, that are avoidable by reasonable action [4], makes it clear that understanding, documenting, and measuring inequity are crucial steps in determining this “reasonable action.” However, rigorous measurement and accurate evaluation of the effects of policies on health equity are not yet universal despite the CSDH calling for researchers to measure and understand the problem and assess the impact of action.

PLOS and PLOS Medicine have long had an interest in health equity. The first article PLOS Medicine ever published [5] discussed the 1994 International Conference on Population and Development (ICPD), in which unequal access to reproductive rights and its consequences were key concepts. PLOS Neglected Tropical Diseases’ first editorial, entitled “A New Voice for the Poor” [6], noted that “The neglected tropical diseases … represent some of humankind’s most ancient scourges and possibly our greatest global health disparities.” Over the years we have provided a forum for the discussion of many other aspects of health equity, including a paper published in November 2011 by Piroska Östlin and colleagues, which explicitly stated that   “Influencing regional and national research priorities on equity and health and their implementation requires joint efforts towards creating a critical mass of researchers, expanding collaborations and networks, and refining norms and standards” [7].

Another specific interest of PLOS Medicine, that of improving the reporting and conduct of research, now aligns with the goals of health equity and this call for refining of standards noted by Östlin and colleagues. We have been involved in the development and publication of revisions to the specific guidelines CONSORT (Consolidated Standards of Reporting Trials) [8] and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (previously QUOROM) guidelines [9] and overarching guidelines on developing reporting guidelines [10]; we have also supported the EQUATOR initiative on guidelines more generally [11]. We are therefore particularly pleased to be publishing this month the PRISMA-Equity 2012 extension [12], drafted during a meeting earlier this year (which included one author of this Editorial, VB), which provides reporting guidelines for systematic reviews with a specific focus on health equity. Most guidelines or extensions to reporting guidelines pertain to technical aspects, for example to improve the reporting of a specific study design such as cluster randomized trials, or for a specific intervention, such as acupuncture. Instead, the PRISMA-Equity 2012 extension is specifically aimed at improving the reporting of the relatively small proportion of systematic reviews in which health equity is a key focus.

At first sight, these guidelines may not fit into the usual technical reasons for the development of reporting guidelines. One issue discussed was whether moral reasons also drove a need for these guidelines. By developing this pragmatic tool, could they do more than just bring clarity to the reporting of specific papers; for example, could a reporting guideline even change outcomes? One paper cited by Welch and colleagues shows that vitamin A [13] has the largest absolute impact on mortality reduction for children with lowest nutritional status. Having that evidence presented as clearly as possible could potentially make the difference between an intervention being appropriately targeted, or not.

One of the original reporting guidelines, CONSORT, has done an enormous amount to raise awareness of the need for good reporting in this most experimental of human studies. Has it done more? The originators of CONSORT tend to shy away from this suggestion but guideline developers sometimes say that a good guideline is like a light shone into an untidy room; it does not tidy the room but shows where the mess is. Perhaps if the light were even turned on at the beginning of a study, there would be less “mess” throughout—and published results would also be clearer and more accurate. So, by shining a light on health equity research, as Welch and colleagues suggest, by providing “structured guidance on transparently reporting these methods and results,” the PRISMA-Equity 2012 guidelines have the potential to not only improve the state of the published literature, but also to “legitimize and emphasize the importance of reporting health equity results.” We are happy to support these dual aims and will endorse the use of these guidelines.

Author Contributions 

Wrote the first draft of the manuscript: VB. Contributed to the writing of the manuscript: VB EV JC PS MW LC. ICMJE criteria for authorship read and met: VB EV JC PS MW LC. Agree with manuscript results and conclusions: VB EV JC PS MW LC.

References

– World Health Organization (2012) Equity. Geneva: World Health Organization.

– Osborn DPJ, Horsfall L, Hassiotis A, Petersen I, Walters K, et al. (2012) Access to Cancer Screening in People with Learning Disabilities in the UK: Cohort Study in the Health Improvement Network, a Primary Care Research Database. PLoS ONE 7 (8) e43841 doi:10.1371/journal.pone.0043841. .

– Albanese E, Liu Z, Acosta D, Guerra M, Huang Y, et al. (2011) Equity in the Delivery of Community Healthcare to Older People: Findings from 10/66 Dementia Research Group Cross-sectional Surveys in Latin America, China, India and Nigeria. BMC Health Serv Res 11: 153 doi:10.1186/1472-6963-11-153. .

– World Health Organization (2008) Closing the Gap in a Generation: Health Equity through Action on the Social Determinants of Health. Commission on Social Determinants of Health Final Report. Geneva: World Health Organization. Available: http://www.who.int/social_determinants/t​hecommission/finalreport/en/index.html. Accessed: 26 September 2012.

– El Feki S (2004) The Birth of Reproductive Health: A Difficult Delivery. PLoS Med 1 (1) e9 doi:10.1371/journal.pmed.0010009. .

– Hotez P (2007) A New Voice for the Poor. PLoS Negl Trop Dis 1 (1) e77 doi:10.1371/journal.pntd.0000077. .

– Östlin P, Schrecker T, Sadana R, Bonnefoy J, Gilson L, et al. (2011) Priorities for Research on Equity and Health: Towards an Equity-Focused Health Research Agenda. PLoS Med 8 (11) e1001115 doi:10.1371/journal.pmed.1001115. .

– Schulz KF, Altman DG, Moher D (2010) for the CONSORT Group (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med 7 (3) e1000251 doi:10.1371/journal.pmed.1000251. .

– Moher D, Liberati A, Tetzlaff J, Altman DG (2009) The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6 (7) e1000097 doi:10.1371/journal.pmed.1000097. .

– Moher D, Schulz KF, Simera I, Altman DG (2010) Guidance for Developers of Health Research Reporting Guidelines. PLoS Med 7 (2) e1000217 doi:10.1371/journal.pmed.1000217. .

EQUATOR Network (2012) Home page. Available: http://www.equator-network.org/ Accessed 26 September 2012.

– Welch V, Petticrew M, Tugwell P, Moher D, O’Neill J, et al. (2012) PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med 9 (10) e1001333 doi:10.1371/journal.pmed.1001333. .

– Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA (2010) Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev Issue 12. Art. No.: CD008524. doi:10.1002/14651858.CD008524.pub2. .

Policy Forum – Public Health: Optimizing Investments in Malaria Treatment and Diagnosis

Science        
2 November 2012 vol 338, issue 6107, pages 569-712
http://www.sciencemag.org/current.dtl

Policy Forum – Public Health
Optimizing Investments in Malaria Treatment and Diagnosis
Justin M. Cohen, Aaron M. Woolsey, Oliver J. Sabot, Peter W. Gething, Andrew J. Tatem, and Bruno Moonen
Science 2 November 2012: 612-614.

Better targeting of antimalarials to people who need them will maximize the impact of interventions in the private sector.

Summary
The Roll Back Malaria (RBM) Partnership has set an ambitious target of achieving near zero deaths from malaria by 2015 (1). Scale-up of insecticide-treated nets, indoor residual spraying of insecticide, and increased access to treatment with artemisinin-based combination therapies (ACTs) over the past decade have led to reductions in malaria incidence of more than 50% in 43 countries, including 8 in Africa (2). However, as an estimated 655,000 malaria deaths still occurred in 2010 (2), with the great majority in sub-Saharan Africa, substantial challenges remain.

Policy Forum – From Financing to Fevers: Lessons of an Antimalarial Subsidy Program

Science        
2 November 2012 vol 338, issue 6107, pages 569-712
http://www.sciencemag.org/current.dtl

Policy Forum – Public Health
From Financing to Fevers: Lessons of an Antimalarial Subsidy Program
Ramanan Laxminarayan, Kenneth Arrow, Dean Jamison, and Barry R. Bloom
Science 2 November 2012: 615-616.

Better approaches to affordable drugs, diagnostic tests, and patient-centered treatment are needed in Africa.

Summary
In 2001, the World Health Organization (WHO) recommended that countries use artemisinin-based combination therapies (ACTs) to treat malaria patients (1), as continued use of artemisinin monotherapies and substandard drugs had the potential to lead to widespread resistance to artemisinin, the most effective drug for malaria. But ACTs were unaffordable for most people in malaria-endemic countries, particularly in the private for-profit sector where most people seek treatment. Artemisinin monotherapies and the threat of resistance remain a problem. Resistance has now emerged in Cambodia and is spreading to Myanmar and Vietnam (2). Despite WHO’s efforts, monotherapies are produced by 37 pharmaceutical companies and marketed in 29 countries (3). Although resistance to artemisinin had not been detected at the time of the Institute of Medicine (IOM) report in 2004 (4), an IOM committee proposed a global subsidy high in the distribution chain, both to make ACTs inexpensive and to displace artemisinin monotherapy and other ineffective drugs.

Opinion – Europe Combating Poverty at Its Roots – David Cameron

Wall Street Journal
http://online.wsj.com/home-page
Accessed 3 November 2012

Opinion – Europe
Combating Poverty at Its Roots
Economic development requires aid, but also sound institutions. Britain can lead on both fronts.
By DAVID CAMERON

Excerpt
There is an old debate between those who say the way to tackle global poverty is to spend more on aid and those who believe instead that the solution is to deal with the weak institutions, corruption and conflict in developing countries. The truth is that right now, we need to do both.

We need to honor our promises to the poor, because people are dying unnecessarily and our aid is needed to save them. But we also need to tackle the causes of poverty, not just its symptoms. And that means a radical new approach to supporting what I call “the golden thread” of conditions that enable open economies and open societies to thrive: the rule of law, the absence of conflict and corruption, and the presence of property rights and strong institutions. It is only when people can get a job and a voice that they can take control of their own destiny and a build a future free from poverty.

I believe Britain is in a unique position to lead this new approach…

http://online.wsj.com/article/SB10001424052970204712904578090571423009066.html?KEYWORDS=cameron

From Google Scholar: Dissertations, Theses, Selected Journal Articles

From Google Scholar: Dissertations, Theses, Selected Journal Articles

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells
KC Kwon, D Verma, ND Singh, R Herzog, H Daniell – Advanced Drug Delivery …, 2012
Abstract Among 12 billion injections administered annually, unsafe delivery leads to> 20
million infections and> 100 million reactions. In an emerging new concept, freeze-dried plant
cells (lettuce) expressing vaccine antigens/biopharmaceuticals are protected in the…

Inactivated poliovirus vaccine: The fog of uncertainty is lifting!
T Jacob John – Indian Pediatrics, 2012
India achieved zero transmission of wild polioviruses (WPVs) in 2011. On 25 February,
2012, the World Health Organization (WHO) removed India from the list of WPV-endemic
countries. Formal certification of eradication requires three years without WPVs, expected…

Did the FDA Fast Track Gardasil At the Risk of Adolescent Girls’ Health? That is the Question.
LCB Botha – J Law Med Ethics, 2012
There are not many public health issues where views are extremely polarized as those
concerning vaccines, and the HPV vaccine Gardasil is a case in point. … Too Fast or Not Too Fast: The FDA’s Approval of Merck’s HPV Vaccine Gardasil. J Law Med Ethics…

Vaccines: The Week in Review 27 October 2012

Editor’s Notes:

Email Summary: Vaccines: The Week in Review is available as a weekly email summary: please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_27 October 2012

Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.

Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…

World Polio Day – 24 October 2012: Statements/Media Releases

World Polio Day – 24 October 2012: Statements/Media Releases

– GAVI Statement: http://www.gavialliance.org/library/news/statements/2012/world-polio-day/

– GAVI Commentary: Building on India’s Success on Polio  by Seth Berkley [see Wall Street Journal in Media Watch below]

– UNICEF: Vaccine suppliers integral to achieving polio free world
http://www.unicef.org/media/media_66238.html
[Excerpt]
COPENHAGEN, 24 October 2012 – On World Polio Day, UNICEF has commended the continued contribution of industry to global polio eradication efforts, particularly in helping meet a 410 million dose gap in 2012 and preventing a 300 million dose gap in 2013.

“This year has proven challenging in terms of oral polio vaccine (OPV) supply due to shortfalls from a few suppliers,” Shanelle Hall, Director UNICEF Supply, said.

Offers received from manufacturers in response to the UNICEF-issued OPV tender for the period covering 2013-2017 identified a gap of approximately 300 million doses for the first half of 2013, which would have seriously affected planned polio campaigns.

“The 2013 supply shortfall has been actively addressed through collaborative efforts by industry to increase or fast-track availability, and coordination with global partners to accelerate WHO prequalification of new products and adjust activity schedules. Sufficient OPV will now be available to meet programmatic requirements for the period,” Ms. Hall added.

UNICEF has also welcomed manufacturer’s contribution to affordable vaccine pricing. Through efforts by multiple manufacturers, cost savings equivalent to nearly 100 million doses are expected over the next five years.

“In times of increasing financial constraint and uncertainty, these savings will have significant impact as we make the final push towards eradicating this disease from the world. Vaccine suppliers, including BioFarma, GlaxoSmithKline, Haffkine, Novartis, Sanofi Pasteur, and the Serum Institute of India, are key partners to the Global Polio Eradication Initiative (GPEI),” said Ms. Hall.

The OPV market is complex and changing, and requires close management and coordination with countries and global programme partners, as well as with industry in order to achieve a polio-free world.

“As global efforts edge closer to realizing this goal, UNICEF remains committed to working with industry to secure OPV at affordable prices, and to ensure potential supply-related challenges are minimised,” she said…

GPEI Update: Polio this week – As of 24 Oct 2012

Update: Polio this week – As of 24 Oct 2012
Global Polio Eradication Initiative

[Editor’s Extract]
– World Polio Day, October 24: Polio eradication partners around the world are marking the first World Polio Day since India was removed from the list of countries with active transmission of wild poliovirus. This development opened up a historic opportunity to complete polio eradication in the remaining endemic countries, powered by the World Health Assembly declaration of an ‘emergency for global public health’ and implemented through national emergency programmes run by the governments of Afghanistan, Nigeria and Pakistan.

– Since World Polio Day last year, the number of new cases of polio has declined by 64% (from 489 at this time last year to 175 this year).

– The next Independent Monitoring Board (IMB) meeting will take place next week in London, United Kingdom. During its deliberations, the IMB will review the latest status of the global polio eradication effort and progress and challenges with implementing national polio emergency action plans. The IMB’s meeting report is anticipated to be finalized in November.

Afghanistan
– One new WPV case was reported in the past week (WPV1 from Kandahar), bringing the total number of cases for 2012 to 26. The most recent case had onset of paralysis on 1 October (WPV1 from Paktya).
– The ‘Ending Polio Is My Responsibility’ social mobilization and media campaign continues to be rolled out, with public service announcements airing on TV and radio, and billboards set up around the country.

Nigeria
– Two new WPV cases were reported in the past week (WPV1s from Katsina), bringing the total number of cases for 2012 to 97. One of the newly-reported cases is the most recent case in the country, and had onset of paralysis on 23 September.

Pakistan
– Three new WPV cases were reported in the past week (two WPV1s from Khyber Pakhtunkhwa – KP – and one WPV1 from Balochistan), bringing the total number of cases for 2012 to 47. The newly-reported case from Balochistan is the most recent in the country, and had onset of paralysis on 2 October.
– Additionally, one new cVDPV2 case was reported, in Balochistan, from September.

Horn of Africa
– Outbreak response is ongoing in Kenya and parts of Somalia, following recent confirmation of a cVDPV2 outbreak in a Somali refugee camp in Dadaab, Kenya, and Kismayo, south-central Somalia.

WHO: Fact Sheet – Poliomyelitis October 2012

WHO: Fact Sheet – Poliomyelitis
Fact sheet N°114
October 2012

Key facts [Excerpt]
– Polio (poliomyelitis) mainly affects children under five years of age.

– One in 200 infections leads to irreversible paralysis. Among those paralysed, 5% to 10% die when their breathing muscles become immobilized.

– Polio cases have decreased by over 99% since 1988, from an estimated 350 000 cases then, to 650 reported cases in 2011. The reduction is the result of the global effort to eradicate the disease.

– In 2012, only three countries (Afghanistan, Nigeria and Pakistan) remain polio-endemic, down from more than 125 in 1988.

– As long as a single child remains infected, children in all countries are at risk of contracting polio. Failure to eradicate polio from these last remaining strongholds could result in as many as 200 000 new cases every year, within 10 years, all over the world.

– In most countries, the global effort has expanded capacities to tackle other infectious diseases by building effective surveillance and immunization systems…

http://www.who.int/mediacentre/factsheets/fs114/en/index.html

Weekly Epidemiological Record (WER) for 26 October 2012

The Weekly Epidemiological Record (WER) for 26 October 2012, vol. 87, 43 (pp. 413–420) includes:
– Outbreak news
. Dengue fever in Madeira, Portugal
. Marburg haemorrhagic fever, Uganda
– Progress towards poliomyelitis eradication in Chad, January 2011–August 2012
– Monthly report on dracunculiasis cases, January–August 2012

http://www.who.int/entity/wer/2012/wer8743.pdf

ACIP Meeting Update: 24 October 2012

ACIP Meeting Update: 24 October 2012

CDC Advisory Committee on Immunization Practices Recommends HibMenCY for Infants at Increased Risk for Meningococcal Disease
[Excerpt]
The Advisory Committee for Immunization Practices voted today 13 to 1, with 1 abstention, to recommend that infants at increased risk for meningococcal disease should be vaccinated with 4 doses of HibMenCY at 2, 4, 6, and 12 through 15 months.  These include infants with recognized persistent complement pathway deficiencies and infants who have anatomic or functional asplenia including sickle cell disease. HibMenCY can be used in infants ages 2 through 18 months who are in communities with serogroup C and Y meningococcal disease outbreaks…

CDC Advisory Committee for Immunization Practices Recommends Tdap Immunization for Pregnant Women
[Excerpt]
The Advisory Committee for Immunization Practices voted today 14 to 0, with one abstention, to recommend that providers of prenatal care implement a Tdap immunization program for all pregnant women.  Health-care personnel should administer a dose of Tdap during each pregnancy irrespective of the patient’s prior history of receiving Tdap.  If not administered during pregnancy, Tdap should be administered immediately postpartum.

This builds upon a previous recommendation made by ACIP in June 2011 to administer Tdap during pregnancy only to women who have not previously received Tdap. By getting Tdap during pregnancy, maternal pertussis antibodies transfer to the newborn, likely providing protection against pertussis in early life, before the baby starts getting DTaP vaccines. Tdap will also protect the mother at time of delivery, making her less likely to transmit pertussis to her infant. If not vaccinated during pregnancy, Tdap should be given immediately postpartum, before leaving the hospital or birthing center.

The U.S. remains on track to have the most reported pertussis cases since 1959, with more than 32,000 cases already reported along with 16 deaths, the majority of which are in infants…

PAHO: Recommendation Calls for Exploring Collaboration between Public Vaccine Producers in the Americas

PAHO: Recommendation Calls for Exploring Collaboration between Public Vaccine Producers in the Americas

PAHO’s Technical Advisory Group (TAG) on Vaccine-preventable Diseases “…recommended that opportunities for collaboration between public vaccine producers in the Americas be explored with a view to incentivizing regional production in order to meet local needs. This recommendation arises from the challenges currently being faced to guarantee a steady supply of priority vaccines and maintain the achievements to date in controlling and eradicating such diseases as poliomyelitis, measles, and rubella.” The Technical Advisory Group recommended that PAHO/WHO convene a working group, bringing together representatives of public vaccine producers in Latin America and the Caribbean, “to identify common areas of activity and draft a regional strategy for vaccine research, development, and production.”

The announcement noted that there are 40 vaccine providers in the world, 15 of which produce 95% of the total output, and 70% of vaccine production takes place in developing countries. In the Americas there are six public sector vaccine manufacturers, located in Argentina, Brazil, Colombia, Cuba, Mexico, and Venezuela. In addition, “the supply of traditional vaccines against polio, yellow fever, and whooping cough (also called pertussis), diphtheria, and tetanus continues to be erratic and often falls short of meeting the needs of the countries in the Region, which acquire them at an affordable price through the PAHO Revolving Fund. These vaccines are still essential.” However, TAG noted in the conclusions of its meeting that “they are no longer of commercial interest to the pharmaceutical companies, which in many cases have ceased to produce them or else have turned their interest toward the preparation of new combined vaccines.”

According to the conclusions of the meeting, “the establishment of agreements for technology transfer between the transnational pharmaceutical industry and producers in the Region has not yet been translated into improved local capacity to produce new vaccines. Hence, there is need for more in-depth analysis of the role that regional producers can play in meeting the needs of the countries of the Americas for high-quality, safe, and effective vaccines.” The PAHO/WHO Technical Advisory Group on Vaccine-preventable Diseases met from October 17 to 19 in Washington, D.C., to examine current issues and make recommendations on vaccination against polio, rotavirus, whooping cough, measles, rubella, and cholera, as well as to consider prospects for ramping up regional vaccine production capacity. http://new.paho.org/hq/index.php?option=com_content&view=article&id=7364%3Arecommendation-calls-for-exploring-collaboration-between-public-vaccine-producers-in-the-americas&catid=740%3Anews-press-releases&Itemid=1926&lang=en&Itemid=1926

GAVI initiatives applauded in Japan

Media Release: GAVI initiatives applauded in Japan
Programmes in public-private partnership, such as IFFIm, held up as models for Japanese corporate sector
Tokyo, 11 October 2012 – [Excerpt]
GAVI’s success in partnering with the private sector was highlighted at a global health symposium of Japanese companies in Tokyo today, supported by the Japanese Ministry of Foreign Affairs.

Companies can “make a reasonable profit and help people at the same time,” said Shiro Konuma, director of the Global Health Policy Division within the Japanese Ministry of Foreign Affairs.

“Governments always must keep in mind the raison d’etre of private companies. That is the starting point. But we all share the responsibility to help save lives.”

Vaccine bonds
Japan recently made its second direct donation to GAVI, and the Japanese public has been responsible for about a quarter of GAVI’s funding through Japan’s uridashi bond market, noted GAVI CEO Seth Berkley, a featured speaker alongside those from the Health & Global Policy Institite (HGPI) think tank, and a panel discussion with five Japanese companies and UNICEF.

Among them was Daiwa Securities, which helped introduce “vaccine bonds” in Japan to benefit GAVI through IFFIm, the International Finance Facility for Immunisation. IFFIm overall has raised US$ 3.7 billion through bonds backed by the pledges of nine donor governments, funding about half of GAVI’s programmes, Berkley notes. And about US$ 2 billion of it has come from Japanese investors.

IFFIm link
IFFIm was consistently cited by the panel as an example of good business that has benefited public health. It “seems like water and oil, but IFFIm is the link,” said Satoru Yamamoto, director/head of International Investors Services at Daiwa. Underwriters like Daiwa can expand and market their business to Japanese investors, who secure both a financial and a social return…

http://www.iffim.org/library/news/press-releases/2012/gavi-initiatives-applauded-in-japan/

Meeting: WHO – Strategic Advisory Group of Experts (SAGE) on Immunization – 6-8 November 2012, Geneva

Meeting: WHO – Strategic Advisory Group of Experts (SAGE) on Immunization
6-8 November 2012, Geneva

[Selected agenda topics]:
– Report from GAVI
– Global polio eradication initiative
– DoV – GVAP (GVAP key steps to implementation; Decade of Vaccine M&E/Accountability Framework; GVAP Costing, Financing and impact update and tracking commitments; Independent review of progress and reporting to governing bodies)
– Hib immunization schedules
– Measles and rubella status report
– Vaccination in humanitarian emergencies
– New vaccine introduction in middle-income countries: current initiatives to address financial challenges

Draft Agenda at 22 October 2012:
http://www.who.int/entity/immunization/sage/Annotated_draft_Agenda_6-8_Nov_SAGE_2012_22Oct.pdf

Symposium: Second Global Symposium on Health Systems Research (HSR) 31 October–3 November 2012 – Beijing, China

Symposium: Second Global Symposium on Health Systems Research (HSR)
31 October–3 November 2012 – Beijing, China

The Symposium will be dedicated to evaluating progress, sharing insights and recalibrating the agenda of science to accelerate universal health coverage (UHC).

A primary theme for the symposium will be innovation and inclusion, highlighting ‘neglected’ themes such as research on neglected public health priorities, causes of exclusion of populations or problems, and on what works in reducing these exclusions.

Each day, 17 concurrent sessions will provide examples of innovations across all health systems building blocks that facilitate faster progress towards universal health coverage in an affordable manner.

In addition, the WHO strategy on health systems research and the member-based Society for HSR will be launched. Anticipated is the establishment of a Beijing Agenda for further advancing the HSR and in particular, the initiation of a process to construct and agree on measures to monitor UHC.

All plenary sessions will be webcast live and are available from the Symposium web site’s home page. In addition, WHO will be tweeting daily from the meeting.

Second Global Symposium on Health Systems Research (HSR)

Commentary: Call to Action on World Pneumonia Day

Emerging Infectious Diseases
Volume 18, Number 11—November 2012
http://www.cdc.gov/ncidod/EID/index.htm

Commentaries
Call to Action on World Pneumonia Day
PDF Version  [PDF – 155 KB – 2 pages]
R. Hajjeh and C. G. Whitney

[Excerpt]
This month, on November 12, the world will recognize the fourth annual World Pneumonia Day. First launched in 2009 by a coalition of global health leaders (1), World Pneumonia Day aims to raise awareness about pneumonia’s toll on the world’s children and to promote interventions to protect against, treat, and prevent the disease. Pneumonia continues to be the leading killer of young children around the world, causing ≈14% of all deaths in children 1 month to 5 years of age (2). It is a critical disease for countries to conquer in order to reach Millennium Development Goal 4: reducing the child mortality rate by two thirds from 1990 to 2015 (3). Most children who die from pneumonia live in developing countries, where such factors as malnutrition, crowding, and lack of access to quality health care increase the risk for death. Pneumonia kills few children in industrialized countries, although it remains among the top 10 causes of deaths in the United States, for example, because of deaths in older adults (4).

Fortunately, many interventions are now available to reduce deaths due to pneumonia among children throughout the world. On the first World Pneumonia Day in 2009, the World Health Organization and the United Nations Children’s Fund, together with many global experts and partners, launched the Global Action Plan for Prevention and Control of Pneumonia (GAPP) (5). GAPP recommends a strategy of prevention, protection, and treatment that is designed to implement readily available interventions that can reduce pneumonia deaths in children. GAPP focuses on improving nutrition (through measures such as exclusive breastfeeding), increasing access to vaccines that protect from agents that cause pneumonia (such as Haemphilus influenzae type b and pneumococcal vaccines), reducing exposure to indoor air pollution, and increasing access to antimicrobial drugs that can treat pneumonia…

Integrating Genome-based Informatics to Modernize Global Disease Monitoring, Information Sharing, and Response

Emerging Infectious Diseases
Volume 18, Number 11—November 2012
http://www.cdc.gov/ncidod/EID/index.htm

Online Reports
Integrating Genome-based Informatics to Modernize Global Disease Monitoring, Information Sharing, and Response
F. M. Aarestrup et al.

Abstract
The rapid advancement of genome technologies holds great promise for improving the quality and speed of clinical and public health laboratory investigations and for decreasing their cost. The latest generation of genome DNA sequencers can provide highly detailed and robust information on disease-causing microbes, and in the near future these technologies will be suitable for routine use in national, regional, and global public health laboratories. With additional improvements in instrumentation, these next- or third-generation sequencers are likely to replace conventional culture-based and molecular typing methods to provide point-of-care clinical diagnosis and other essential information for quicker and better treatment of patients. Provided there is free-sharing of information by all clinical and public health laboratories, these genomic tools could spawn a global system of linked databases of pathogen genomes that would ensure more efficient detection, prevention, and control of endemic, emerging, and other infectious disease outbreaks worldwide.

Infectious disease emergence and global change: thinking systemically in a shrinking world

Infectious Diseases of Poverty
2012, 1
http://www.idpjournal.com/content
[Accessed 27 October 2012]
Aims & scope
Infectious Diseases of Poverty is an open access, peer-reviewed journal publishing topic areas and methods that address essential public health questions relating to infectious diseases of poverty. These include various aspects of the biology of pathogens and vectors, diagnosis and detection, treatment and case management, epidemiology and modeling, zoonotic hosts and animal reservoirs, control strategies and implementation, new technologies and application. Transdisciplinary or multisectoral effects on health systems, ecohealth, environmental management, and innovative technology are also considered.

IDP aims to identify and assess research and information gaps that hinder progress towards new interventions for a particular public health problem in the developing world. Moreover, to provide a platform for discussion of the issues raised, in order to advance research and evidence building for improved public health interventions in poor settings.

Research Article  
Infectious disease emergence and global change: thinking systemically in a shrinking world
Colin D Butler Infectious Diseases of Poverty 2012, 1:5 (25 October 2012)

Abstract [Open Access]
Background
Concern intensifying that emerging infectious diseases and global environmental changes that could generate major future human pandemics.

Method
A focused literature review was undertaken, partly informed by a forthcoming report on environment, agriculture and infectious diseases of poverty, facilitated by the Special Programme for Tropical Diseases.

Results
More than ten categories of infectious disease emergence exist, but none formally analyse past, current or future burden of disease. Other evidence suggests that the dominant public health concern focuses on two informal groupings. Most important is the perceived threat of newly recognised infections, especially viruses that arise or are newly discovered in developing countries that originate in species exotic to developed countries, such as non-human primates, bats and rodents. These pathogens may be transmitted by insects or bats, or via direct human contact with bushmeat. The second group is new strains of influenza arising from intensively farmed chickens or pigs, or emerging from Asian “wet markets” where several bird species have close contact. Both forms appear justified because of two great pandemics: HIV/AIDS (which appears to have originated from bushmeat hunting in Africa before emerging globally) and Spanish influenza, which killed up to 2.5% of the human population around the end of World War I. Insufficiently appreciated is the contribution of the milieu which appeared to facilitate the high disease burden in these pandemics. Additionally, excess anxiety over emerging infectious diseases diverts attention from issues of greater public health importance, especially: (i) existing (including neglected) infectious diseases and (ii) the changing milieu that is eroding the determinants of immunity and public health, caused by adverse global environmental changes, including climate change and other components of stressed life and civilisation-supporting systems.

Conclusions
The focus on novel pathogens and minor forms of anti-microbial resistance in emerging disease literature is unjustified by their burden of disease, actual and potential, and diverts attention from far more important health problems and determinants. There is insufficient understanding of systemic factors that promote pandemics. Adverse global change could generate circumstances conducive to future pandemics with a high burden of disease, arising via anti-microbial and insecticidal resistance, under-nutrition, conflict, and public health breakdown.

Opinion: Technology innovation for infectious diseases in the developing world

Infectious Diseases of Poverty
2012, 1
http://www.idpjournal.com/content
[Accessed 27 October 2012]
Aims & scope
Infectious Diseases of Poverty is an open access, peer-reviewed journal publishing topic areas and methods that address essential public health questions relating to infectious diseases of poverty. These include various aspects of the biology of pathogens and vectors, diagnosis and detection, treatment and case management, epidemiology and modeling, zoonotic hosts and animal reservoirs, control strategies and implementation, new technologies and application. Transdisciplinary or multisectoral effects on health systems, ecohealth, environmental management, and innovative technology are also considered.

IDP aims to identify and assess research and information gaps that hinder progress towards new interventions for a particular public health problem in the developing world. Moreover, to provide a platform for discussion of the issues raised, in order to advance research and evidence building for improved public health interventions in poor settings.

Opinion  
Technology innovation for infectious diseases in the developing world
Anthony D So, Quentin Ruiz-Esparza Infectious Diseases of Poverty 2012, 1:2 (25 October 2012)

Abstract [Open Access]
Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low- and middle-income countries (LMICs). However, a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs. While the pharmaceutical industry views emerging economies as potential new markets, most of the world’s poorest bottom billion now reside in middle-income countries–a fact that has complicated tiered access arrangements. However, product development partnerships–particularly those involving academic institutions and small firms–find commercial opportunities in pursuing even neglected diseases; and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation. Such innovation will be shaped by 1) access to building blocks of knowledge; 2) strategic use of intellectual property and innovative financing to meet public health goals; 3) collaborative norms of open innovation; and 4) alternative business models, some with a double bottom line. Facing such resource constraints, LMICs are poised to develop a new, more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.

Comment: Can WHO survive?

The Lancet  
Oct 27, 2012  Volume 380  Number 9852  p1445 – 1530
http://www.thelancet.com/journals/lancet/issue/current

Comment
Offline: Can WHO survive?
Richard Horton

Preview
The title of last week’s Global Health Lab, held at the London School of Hygiene and Tropical Medicine, was meant to incite interest, not signal aggression. But some interpreted the symposium as an attack before it had even taken place. I was texted, tweeted, and emailed to encourage diplomacy. None of these rearguard protective manoeuvres turned out to be necessary. In our debate about WHO, led by Gill Walt (from the School), Kathryn Tyson (UK Department of Health), Anders Nordström (Sweden’s Ambassador for Global Health), and Martin McKee (Director of ECOHOST), the answer to the question was unambiguously “yes”.

Riding the waves: optimism and realism in the treatment of TB

The Lancet  
Oct 27, 2012  Volume 380  Number 9852  p1445 – 1530
http://www.thelancet.com/journals/lancet/issue/current

Perspectives: The art of medicine
Riding the waves: optimism and realism in the treatment of TB
Helen Bynum

Preview
The history of treatment for pulmonary tuberculosis can be divided into two eras: before and after the advent of antibiotics. What had been treated but had proven incurable for millennia became curable in the early 1950s, when the combination of streptomycin, para-aminosalicylic acid (PAS), and isoniazid effectively cleansed the body of invading mycobacteria. Subsequently more easily administered, better-tolerated drugs advanced treatment protocols and brought greater benefits. It would be wrong to suggest that drugs were the only solution; education, screening, vaccination, and prevention measures were essential.

Control of cholera in Africa by vaccination – Zanzibar

The Lancet Infectious Disease
Nov 2012  Volume 12  Number 11  p817 – 896
http://www.thelancet.com/journals/laninf/issue/current

Comment
A case for control of cholera in Africa by vaccination
Jan Holmgren

Preview
In The Lancet Infectious Diseases, Ahmed Khatib and colleagues1 describe the direct and indirect (herd protection) effectiveness of an oral killed Vibrio cholerae whole-cell B-subunit cholera vaccine deployed in a mass vaccination campaign in almost 50 000 individuals in Zanzibar, east Africa, a region that has had regular outbreaks of cholera since 1978. Two vaccine doses were offered and given through the public health services to individuals in the study areas aged 2 years and older. Over the next 14 months the vaccine was shown to confer 79% direct protection against cholera and also significant indirect protection (50% in the non-vaccinated residents and as much as 75–90% in clusters with the highest vaccine coverage).

Articles
Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study
Ahmed M Khatib, Mohammad Ali, Lorenz von Seidlein, Deok Ryun Kim, Ramadhan Hashim, Rita Reyburn, Benedikt Ley, Kamala Thriemer, Godwin Enwere, Raymond Hutubessy, Maria Teresa Aguado, Marie-Paule Kieny, Anna Lena Lopez, Thomas F Wierzba, Said Mohammed Ali, Abdul A Saleh, Asish K Mukhopadhyay, John Clemens, Mohamed Saleh Jiddawi, Jacqueline Deen

Summary
Background
Zanzibar, in east Africa, has been severely and repeatedly affected by cholera since 1978. We assessed the effectiveness of oral cholera vaccination in high-risk populations in the archipelago to estimate the indirect (herd) protection conferred by the vaccine and direct vaccine effectiveness.

Methods
We offered two doses of a killed whole-cell B-subunit cholera vaccine to individuals aged 2 years and older in six rural and urban sites. To estimate vaccine direct protection, we compared the incidence of cholera between recipients and non-recipients using generalised estimating equations with the log link function while controlling for potential confounding variables. To estimate indirect effects, we used a geographic information systems approach and assessed the association between neighbourhood-level vaccine coverage and the risk for cholera in the non-vaccinated residents of that neighbourhood, after controlling for potential confounding variables. This study is registered with ClinicalTrials.gov, number NCT00709410.

Findings
Of 48 178 individuals eligible to receive the vaccine, 23 921 (50%) received two doses. Between February, 2009, and May, 2010, there was an outbreak of cholera, enabling us to assess vaccine effectiveness. The vaccine conferred 79% (95% CI 47—92) direct protection against cholera in participants who received two doses. Indirect (herd) protection was shown by a decrease in the risk for cholera of non-vaccinated residents within a household’s neighbourhood as the vaccine coverage in that neighbourhood increased.

Interpretation
Our findings suggest that the oral cholera vaccine offers both direct and indirect (herd) protection in a sub-Saharan African setting. Mass oral cholera immunisation campaigns have the potential to provide not only protection for vaccinated individuals but also for the unvaccinated members of the community and should be strongly considered for wider use. Because this is an internationally-licensed vaccine, we could not undertake a randomised placebo-controlled trial, but the absence of vaccine effectiveness against non-cholera diarrhoea indicates that the noted protection against cholera could not be explained by bias.

Funding
Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, and the South Korean Government.